These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33554103)

  • 1. A
    Calame DG; Herman I; Riviello JJ
    Epilepsy Behav Rep; 2021; 15():100425. PubMed ID: 33554103
    [No Abstract]   [Full Text] [Related]  

  • 2. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment.
    Contreras-García IJ; Gómez-Lira G; Phillips-Farfán BV; Pichardo-Macías LA; García-Cruz ME; Chávez-Pacheco JL; Mendoza-Torreblanca JG
    Brain Sci; 2021 Apr; 11(5):. PubMed ID: 33922424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
    Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
    Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intranasal and oral administration of levetiracetam on the temporal and spatial distributions of SV2A in the KA-induced rat model of SE.
    Zhao W; Li Y; Sun H; Zhang W; Li J; Jiang T; Jiang L; Meng H
    J Cell Mol Med; 2023 Dec; 27(24):4045-4055. PubMed ID: 37845841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi.
    Grimminger T; Pernhorst K; Surges R; Niehusmann P; Priebe L; von Lehe M; Hoffmann P; Cichon S; Schoch S; Becker AJ
    Neurobiol Dis; 2013 Dec; 60():115-25. PubMed ID: 24018139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Connectivity Mapping Using a Novel
    Zhang Y; Heylen L; Partoens M; Mills JD; Kaminski RM; Godard P; Gillard M; de Witte PAM; Siekierska A
    Front Mol Neurosci; 2022; 15():881933. PubMed ID: 35686059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.
    García-Pérez E; Mahfooz K; Covita J; Zandueta A; Wesseling JF
    Epilepsia; 2015 Apr; 56(4):535-45. PubMed ID: 25684406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
    Ohno Y; Tokudome K
    CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke.
    Shetty AK
    Front Neurol; 2013 Nov; 4():172. PubMed ID: 24204362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.